Research Article

Comparative Effects of Three Iron Chelation Therapies on the Quality of Life of Greek Patients with Homozygous Transfusion-Dependent Beta-Thalassemia

Vasilis Goulas,1 Alexandra Kourakli-Symeonidis,2 and Charalambos Camoutsis3

1 Department of Pharmacy, General Hospital of Agrinio, Kokkali Street, 30100 Agrinio, Greece
2 Thalassemia and Hemoglobinopathies Centre, Hematology Division, University Hospital of Patras, Patras, Greece
3 Laboratory of Pharmaceutical Chemistry, Department of Pharmacy, University of Patras, Patras, Greece

Correspondence should be addressed to Vasilis Goulas, elmayoh1@hotmail.com

Received 23 October 2012; Accepted 8 November 2012

1. Introduction

Beta-thalassemia is a genetically inherited disorder characterized by reduced synthesis of the beta-hemoglobin chain which in turn results in reduced synthesis of hemoglobin A (HbA). To date more than 1,000 mutations are known that influence the structure or synthesis of the alpha- and beta-globin chains that make up HbA and which are listed in the HbVar database (HbVar), a database of all the mutations related to thalassemia and the variations of hemoglobin [1, 2]. In Greece, in addition to common mutations with distribution patterns that vary between particular region(s) of the country [3], some rare mutations have been reported. All these mutations are included in the Hellenic National Genetic database, a database that lists mutations of all inherited disorders present in the Greek population [4].

Treatment of patients with thalassemia major consists of regular blood transfusions and iron chelation therapy, which is vital to prevent excess iron buildup in the body. In Europe there are three iron chelating agents available: deferoxamine (DFO, Desferal), an iron chelator given by infusion, and two oral chelators deferiprone (DFP, Ferriprox) and deferasirox (DFX, Exjade). Treatment with iron chelators has significantly increased the life expectancy of affected individuals into the third to fifth decade [5], while simultaneously decreasing the comorbidities of the disease [6].

Despite advancements in care, patients with transfusion-dependent beta-thalassemia still present complications and often suffer from psychological problems due to their lifestyle [7–9]. While the effectiveness of iron chelation therapies has been thoroughly investigated, there is limited comparative information about the benefits of the therapies on the quality of life.
of life and self-esteem of the patients. Furthermore, while Greece is a country with high prevalence of beta-thalassemia, the quality of life of patients presenting with this disease and the effect of the type of iron chelation treatment on the patient’s quality of life have not been evaluated. Thus, the objective of the present study was to compare the quality of life, self-esteem, and satisfaction and adherence to treatment of patients with homozygous transfusion-dependent beta-thalassemia in the Greek population receiving three different chelation treatments and to identify parameters affecting their quality of life. The SF-36 questionnaire was used in order to evaluate the quality of life in the 135 patients of the study. Three other questionnaires were administered which provided important information on factors varying among patients receiving different types of iron chelation therapy.

2. Methods

2.1. Patients. A total of 135 adults with transfusion-dependent homozygous beta-thalassemia attending the Thalassemia Units of the University Hospital of Rio-Patras and of the General Hospital of Agrinio between May 2009 and May 2011 were enrolled in the study. During this time period, 174 homozygous beta-thalassemia patients were attending the aforementioned two units; 39 did not return their questionnaires and did not provide reasons for dropping out of the study. Diagnosis with homozygous transfusion-dependent beta-thalassemia was the only criterion used for inclusion in the study. There were no exclusion criteria. The scientific committee of the study and the local ethics committees of the participating hospitals approved the study. All patients provided written informed consent for their participation.

2.2. Evaluation Questionnaires. All patients were asked to answer the following four questionnaires: (i) the SF-36 questionnaire [10]; (ii) a Wallston’s health locus of control scale, in which the patients answered 18 questions using a 6-point Likert-type scale response format [11] with 1 and 2 = strongly and moderately disagree, respectively, 3 = neither agree nor disagree, and 4, 5, and 6 = slightly, moderately, and strongly agree, respectively; (iii) a self-esteem questionnaire with 13 questions using a 5-point Likert-type scale (with 1 = very well and 5 = very poorly); (iv) a questionnaire about patient satisfaction from their current therapeutic chelator with 41 questions with responses varying from never to always. In addition, personal data and the hematological profile of the patients were obtained in order to be able to better evaluate the quality of life of the patients enrolled in our study.

2.3. Statistical Analysis. All continuous variables are expressed as the mean ± standard deviation (SD). The categorical (nominal) variables are expressed as percentages of the total population. Comparisons of the categorical variables between the three therapies were performed by the chi square test or the Fisher test as appropriate. Differences in the continuous variables between the three groups were assessed by the Kruskal Wallis test. Differences were considered significant when the P value was <0.05.

In order to investigate if chelation treatment is associated with patients’ quality of life, univariate regression analysis was performed in which the eight scales and the two components of the SF-36 were set as dependent variables and chelation treatment was set as the independent variable. Multiple regression analysis was also performed for the two component scores (PCS, MCS) separately in order to evaluate their relationship with clinical and anthropometric characteristics. Specifically, gender, marital status, professional status, physical activity, smoking habits, years since diagnosis, years since chelation treatment onset, and other comorbidities were set as independent variables along with chelation treatment in order to investigate factors associated with the quality of life. Statistical analyses were performed with SPSS version 20.0 for Windows (Cary, NC, USA).

3. Results

3.1. Patient Characteristics. Of the 135 adult patients with homozygous transfusion-dependent beta-thalassemia that were recruited in this study, 59 were males and 76 were females. The patients were divided into three groups based on the therapy they were receiving: the first group was receiving deferoxamine (DFO; Desferal, Novartis), the second group deferasirox (DFX; Exjade, Novartis), and the third group deferoxamine + deferiprone (DFP; Ferriprox, Demo S.A.) combination therapy. The mean age of the patients was 37.3 ± 10.1 for the DFO group, 34.3 ± 7.4 for the DFX group, and 37.8 ± 8.3 for the DFO + DFP group. The differences among the groups were not statistically significant. The demographic characteristics of the patients are shown in Table 1. More than half of the patients (75/135) were receiving DFX, while 39 and 21 were receiving combination therapy and DFO alone, respectively. The majority of the patients receiving DFO (19/21) and DFO + DFP (33/39) were not involved in sports, while 34/70 of DFX patients were, a statistically significant difference (P < 0.0001) (Table 1).

3.2. Disease Characteristics. The disease characteristics of patients of the three groups are presented in Table 2. There were no significant differences among the three groups between their age at the time of diagnosis and their age when DFO treatment began. When examining the comorbidities, the patients receiving DFO had significantly higher percentages of myocardial dysfunction (33.3%) and hepatic dysfunction (38.1%), while 71.4% had undergone splenectomy and 14.3% suffered from allergies (Table 3).

3.3. Results from Questionnaires. The SF-36 questionnaire was used as a measurement of the quality of life of the patients. This questionnaire consists of eight scales (1) physical functioning, (2) role limitations because of physical health problems, (3) bodily pain, (4) general health perceptions, (5) vitality (energy/fatigue), (6) social functioning, (7) role limitations due to emotional problems, and (8) general mental health (psychological distress and...
Table 1: Demographic characteristics and physical activity of the patients.

|                          | DFO (n = 21) | DFX (n = 75) | DFO + DFP (n = 39) | P value |
|--------------------------|--------------|--------------|-------------------|---------|
| Gender                   |              |              |                   |         |
| Male                     | 15           | 40           | 21                | 53.8    | NS     |
| Female                   | 6            | 35           | 18                | 46.2    |         |
| Marital status           |              |              |                   |         |
| Single                   | 12           | 48           | 26                | 66.7    |         |
| Married                  | 8            | 20           | 11                | 28.2    | NS     |
| Divorced                 | 0            | 0            | 0                 | 0.0     | NS     |
| Did not answer           | 1            | 3            | 2                 | 5.1     |         |
| Parenthood               |              |              |                   |         |
| Yes                      | 5            | 12           | 10                | 25.6    |         |
| No                       | 15           | 60           | 28                | 71.8    | NS     |
| Did not answer           | 1            | 3            | 2                 | 2.6     |         |
| Physical activity        |              |              |                   |         |
| None/low                 | 8            | 17           | 3                 | 7.7     | NS     |
| Moderate/high            | 13           | 54           | 36                | 92.3    | NS     |
| Did not answer           | 0            | 4            | 0                 | 0.0     |         |
| Sports                   |              |              |                   |         |
| Yes                      | 2            | 34           | 6                 | 15.4    |         |
| No                       | 19           | 36           | 33                | 84.6    | <0.0001|
| Did not answer           | 0            | 5            | 0                 | 0.0     |         |
| Smoking status           |              |              |                   |         |
| Smoker                   | 3            | 15           | 10                | 25.6    | NS     |
| Nonsmoker                | 6            | 36           | 10                | 25.6    | NS     |
| Did not answer           | 12           | 24           | 39                | 48.7    |         |
| Employment status        |              |              |                   |         |
| Employed                 | 16           | 60           | 28                | 71.8    |         |
| Unemployed               | 5            | 12           | 11                | 28.2    | NS     |
| Did not answer           | 0            | 3            | 0                 | 0.0     |         |

DFO: deferoxamine; DFX: deferasirox; DFP: deferiprone; NS: not significant. P values < 0.05 indicate statistical differences between the three groups.

Table 2: Disease characteristics.

|                          | DFO          | DFX          | DFO + DFP     | P value |
|--------------------------|--------------|--------------|---------------|---------|
| Age of disease onset, years | 2.1 ± 2.4  | 2.8 ± 4.5    | 2.3 ± 4.1    | NS      |
| Age at start of DFO treatment, years | 13.1 ± 11.1 | 9.0 ± 9.6    | 11.1 ± 11.6  | NS      |
| Frequency of DFO therapy, times per week | 5.2 ± 1.0  | —            | 4.4 ± 1.9    | <0.0001 |
| Frequency of transfusions per month | 2.2 ± 0.6  | 1.9 ± 0.5    | 2.1 ± 0.7    | NS      |
| Hemoglobin levels prior to transfusion, g/dL | 9.5 ± 0.9 | 10.1 ± 3.4  | 9.7 ± 0.4    | 0.0208  |
| Ferritin levels upon enrollment, ng/mL | 1559.2 ± 1778.1 | 1738.0 ± 1636.9 | 1023.1 ± 944.3 | NS      |

DFO: deferoxamine; DFX: deferasirox; DFP: deferiprone; NS: not significant. P values < 0.05 indicate statistical differences between the three groups. All values are means ± SD.

psychological wellbeing). The scores were calculated for respondents completing 50% or more of the items within a scale. Higher scores represent better health. The type of chelation treatment was proven to be statistically significantly associated with physical functioning (P = 0.048), role limitations due to physical health problems (P = 0.021), bodily pain (P = 0.015), vitality (P < 0.001), and mental health (P = 0.001) (Table 4). Pairwise comparisons performed in the aforementioned scales in order to ascertain differences among the treatments revealed that those who
received DFX or DFO + DFP demonstrated significantly higher mean scores (better quality of life) than patients who received DFO alone, in all scales tested, apart from the bodily pain scale. In the bodily pain scale, only treatment with DFX resulted in a significantly higher mean score than treatment with DFO alone.

For patients with available scores for all 8 scales, the physical health component score (PCS) and the mental health component score (MCS) were derived [10]. Univariate regression analysis demonstrated that the type of chelation treatment was statistically significantly associated with the PCS (Figure 1). In addition, pairwise comparisons revealed that patients who received DFX and combination treatment of DFO + DFP had a significantly higher mean PCS score (better physical health) than patients who received DFO. No statistically significant differences were observed between treatment with DFX and a combination treatment of DFO + DFP.

### Table 3: Frequency of comorbidities or prior splenectomy per group.

| Condition                  | DFO   | DFX   | DFO + DFP | P value |
|----------------------------|-------|-------|-----------|---------|
| Myocardial dysfunction     | 33.3% | 6.7%  | 15.4%     | 0.0058  |
| Hepatic dysfunction        | 38.1% | 6.7%  | 2.6%      | <0.0001 |
| Thyroid disease            | 28.6% | 58.7% | 53.8      | 0.0499  |
| Hypogonadism               | 14.3% | 10.7% | 10.3%     | NS      |
| Splenectomy                | 71.4% | 38.7% | 48.7%     | 0.0319  |
| Allergies                  | 14.3% | 9.3%  | 2.6%      | 0.0487  |

DFO: deferoxamine; DFX: deferasirox; DFP: deferiprone; NS: not significant. P values < 0.05 indicate statistical differences among the three groups.

### Table 4: Association between SF-36 scales and chelation treatment.

| SF-36 scale                        | Chelation treatment | N  | Estimated mean score | 95% CI for estimated mean score | P value* |
|------------------------------------|---------------------|----|-----------------------|---------------------------------|---------|
| Physical functioning               | DFX                 | 72 | 80.3                  | 75.7                            | 84.8    | 0.048 |
|                                   | DFO + DFP           | 19 | 80.3                  | 74.2                            | 87.6    | 0.021 |
|                                   | DFO                 | 33 | 68.4                  | 59.6                            | 77.3    | 0.015 |
| Role limitations due to physical health | DFX             | 71 | 79.9                  | 71.5                            | 88.3    | 0.111 |
|                                   | DFO + DFP           | 17 | 76.5                  | 64.2                            | 88.8    | 0.001 |
|                                   | DFO                 | 33 | 52.9                  | 35.8                            | 70.1    | 0.001 |
| Bodily pain                       | DFX                 | 71 | 80.3                  | 74.4                            | 86.3    | 0.111 |
|                                   | DFO + DFP           | 17 | 73.6                  | 64.9                            | 82.3    | 0.001 |
|                                   | DFO                 | 33 | 60.7                  | 48.6                            | 72.8    | 0.001 |
| General health perceptions        | DFX                 | 70 | 51.6                  | 47.4                            | 55.9    | 0.845 |
|                                   | DFO + DFP           | 17 | 53.1                  | 46.9                            | 59.3    | 0.001 |
|                                   | DFO                 | 33 | 42.3                  | 33.6                            | 50.9    | 0.001 |
| Vitality                          | DFX                 | 71 | 61.8                  | 57.6                            | 65.9    | 0.845 |
|                                   | DFO + DFP           | 17 | 68.5                  | 62.4                            | 74.6    | 0.001 |
|                                   | DFO                 | 33 | 46.2                  | 37.7                            | 54.7    | 0.001 |
| Social functioning                | DFX                 | 71 | 76.4                  | 71.2                            | 81.6    | 0.845 |
|                                   | DFO + DFP           | 17 | 77.3                  | 69.7                            | 85.0    | 0.338 |
|                                   | DFO                 | 33 | 73.5                  | 62.9                            | 84.1    | 0.001 |
| Role limitations due to emotional problems | DFX           | 71 | 77.9                  | 69.6                            | 86.3    | 0.845 |
|                                   | DFO + DFP           | 17 | 71.4                  | 59.2                            | 83.6    | 0.001 |
|                                   | DFO                 | 33 | 64.7                  | 47.7                            | 81.7    | 0.001 |
| Mental health                     | DFX                 | 71 | 65.4                  | 61.1                            | 69.6    | 0.001 |
|                                   | DFO + DFP           | 17 | 65.3                  | 59.1                            | 71.6    | 0.001 |
|                                   | DFO                 | 33 | 46.8                  | 38.1                            | 55.5    | 0.001 |

*Univariate analysis; DFO: deferoxamine; DFX: deferasirox; DFP: deferiprone; NS: not significant. P values < 0.05 indicate statistical differences among the three groups.
The impact of the type of chelation therapy on the PCS was further confirmed by multivariate regression analysis \((P = 0.001)\) in which anthropometric measures, specifically, gender, marital status, professional status, physical activity, smoking habits, years since diagnosis, years since chelation treatment onset, and other comorbidities were included. In this analysis, it also appeared that being married \((P < 0.001)\) and a diagnosis of \(<30\) years \((P = 0.007)\) positively impacted the PCS score. Multivariate analysis with the MCS using the same anthropometric values listed above revealed that chelation treatment significantly impacted the MCS score \((P = 0.009)\).

In addition, patients completed Wallston’s questionnaire pertaining to the control of their health. This questionnaire assesses five dimensions of control of one’s health, “internal,” “chance,” “powerful others,” “doctors,” and “other people.” For each of these five dimensions, higher scores represent those that more strongly believe that they have little control over their health and that their health is dependent on the specific dimension examined [11]. According to the results of Wallston’s 18-item Health Locus of Control Scale, patients only differed slightly \((P = 0.0438)\) in their belief that their doctors had control of their personal health status. The highest score \((13.4 \pm 2.1)\) was observed in the DFO group of patients compared to the DFX \((11.5 \pm 3.0)\) and DFO + DFP \((12.1 \pm 3.0)\) groups, meaning that those were the ones that felt that their doctors had greatest control over their health. There were no statistically significant differences noted among the groups for the other four dimensions.

The majority of patients felt they benefited from receiving chelation therapy. However, when asked to rate their satisfaction with their iron chelation therapy, patients receiving DFX were more likely to respond that they did not feel restricted in terms of their night activities. The majority of patients felt they benefited from the unwanted side effects of their treatment \((P = 0.0113)\) and that the treatment negatively influenced their body and skin appearance \((P = 0.0276)\).

Furthermore, patients receiving DFO felt that their treatment limited their ability to work, to attend school, and to perform daily tasks (Figure 2). Specifically, the group receiving DFO were significantly more limited (i.e., had a higher score, 3.2 ± 2.9) than the DFX \((0.5 \pm 0.8)\) and DFO + DFP \((0.4 \pm 0.9)\) groups \((P = 0.0066)\).

The adherence to treatment rate was the lowest in the DFO group compared to the DFX group and the DFO + DFP group \((P < 0.001)\) (Figure 3). In particular, 9.5% of those receiving DFO, compared to 33.3% of those receiving DFX and 20.5% of those receiving DFO + DFP, reported that they always adhered to their treatment, while the respective percentages of those that forgot to take their treatment were 28.6%, 2.7%, and 25.6% for the DFO, DFX, and DFO + DFP groups.

The percentages of patients that felt substantial or major annoyance from the length of their treatment were 23.8% for the DFO group, 12% for the DFX group and 12.8% for the DFO + DFP group. This is in sharp contrast to the percentages of 4.8, 25.3, and 23.1% of the DFO, DFX, and DFO + DFP groups of patients that were not bothered at all from the length of their treatment (overall \(P = 0.0293\)) (Figure 4). In addition, more patients receiving DFO \((19\%)\) felt that their treatment was hard or very hard to receive compared to 6.7% for DFX and 5.1% for DFO + DFP. This is in contrast to 9.5%, 42.7%, and 38.2% of those receiving DFO, DFX, and DFO + DFP, respectively, that felt that receiving their therapy was easy or very easy (overall \(P = 0.0289\), resp.) (Figure 5).

The three groups also differed significantly \((P = 0.0316)\) in their satisfaction to their type of therapy (infusion, oral, or combination) with the majority of patients from all the groups preferring oral therapy.

4. Discussion

One hundred and thirty-five adult beta-thalassemia transfusion-dependent homozygote patients took part in this study. The majority of the patients were single without children, in agreement with previous reports [12]. One-fifth of the patients were unemployed, a not very high percentage
Limitation in their ability to work, attend school, and perform daily tasks

Deferoxamine (DFO)
Deferasirox (DFX)
Deferoxamine + deferiprone (DFO + DFP)

Deferoxamine (DFO)
Deferasirox (DFX)
Deferoxamine + deferiprone (DFO + DFP)

Figure 2: Effect of iron chelation therapy on the ability of the beta-thalassemia patients to perform their daily tasks. A statistically significant difference was noted among the three groups ($P = 0.0066$). Patients receiving DFO were more limited.

if one takes into account that the current unemployment rate of the general population in Greece is about 10% (and rising) and that a previous report showed that this rate was 16.2% two decades ago [13].

The DFO + DFP combination therapy offers a better control of serum ferritin levels, thus requiring less frequent DFO infusions [14]. It was thus not surprising that we found a decreased frequency of transfusions in the DFO + DFP combination group ($P < 0.0001$; Table 2). A higher percentage of DFO patients had comorbidities compared to the other two groups, except for thyroid disease, which was more prevalent in DFX patients. The presence of hepatic dysfunction in patients with homozygous beta-thalassemia has been correlated with iron overload in the liver as well as to chronic hepatitis [15, 16]. It is also notable that patients receiving DFX had the lowest prevalence of myocardiopathy which is in accordance with reports on the ability of DFX to prevent iron overload in the myocardium [17].

The highest rate of patient adherence to treatment was observed in the DFX patients. Adherence to therapy is the most important parameter for successful therapy. In fact low adherence of patients receiving DFO has been linked to the absence of clinical benefit [6]. In a previous study, low adherence to DFO was linked to smoking and to difficulties with self-administering the infusion [18].

Our results about satisfaction and ease of receiving their therapy matched those of previous studies, in which DFX was associated with increased satisfaction to treatment [19, 20]. Importantly, it was shown that switching chelators resulted in increased adherence, regardless of whether the patients switched from the oral to the intravenous chelator or vice versa, although the switch from DFO to DFP occurred more often [19].

According to previous studies, patients receiving DFO were more likely to suffer from depression, fatigue, dyspnea, and decreased physical functioning [21–23]. The majority of patients felt that they could participate in more activities if
they were not receiving DFO [24] in accordance with the results of our study indicating that DFO limited the ability of patients to participate in sports and perform daily functions. Furthermore, the results of our study indicate that patients receiving DFO had lower self-esteem and worse PCS scores. These observations are in agreement with the results of the ITHACA study, in which the PCS score was low for patients receiving DFO [25] and with the study of Abetz et al., in which patients with DFO suffered from low self-esteem [21].

Of the specific components of the SF-36 questionnaire, the type of chelation treatment was proven to be statistically significantly associated with physical functioning, role limitations due to physical health problems, bodily pain, vitality, and mental health. Importantly, the results of our multivariate analysis indicate that the dependence of the PCS score on the type of chelation treatment was not confounded by anthropometric variables, such as gender, marital status, level of physical activity, presence of comorbidities, or smoking status. The importance of the SF-36 questionnaire and the results of the individual scales on the multidisciplinary actions that should be taken for patients with beta-thalassemia have been reported [26, 27].

The study is not without limitations. A randomized controlled clinical trial would be needed to ascertain the cause and effect relationship between quality of life and type of iron chelation therapy. Future studies should be of this design. However, its design as a prospective study of patients attending the hematology units of two major hospitals of Western Greece is ideal for reflecting daily clinical practice and the impact on the quality of life of these patients in “real-life.”

5. Conclusions
In conclusion, our study provides support for differences in the limitations of daily activities, physical activity, and quality of life among patients with transfusion-dependent beta-thalassemia depending on the type of their chelation therapy. Furthermore, the adherence to treatment, the ease and satisfaction from their therapy, and patient self-esteem differed along the three groups. This study highlights the importance of providing beta-thalassemia patients with the optimal chelation treatment based on their individual needs, in order to decrease the presence of unwanted comorbidities and to increase the quality of life, leading to increased adherence and thus resulting in optimal clinical benefit. Furthermore, our results highlight the need of the involvement of a multidisciplinary team in the management of patients with this disease.

Conflict of Interests
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Ethical Approval
The scientific committee of the study and the local ethics committees of the participating hospitals approved the study. Written informed consent was obtained by all the patients.

Acknowledgments
The authors wish to thank John Tavernakis, Maria Kavasi, and Vasiliki Pesli for assistance with collection of the data and patient enrollment. They also wish to express their sincere gratitude to all the patients that participated in this study.

References

[1] R. C. Hardison, D. H. K. Chui, B. Giardine et al., “HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server,” Human Mutation, vol. 19, no. 3, pp. 225–233, 2002.
[2] G. P. Patrinos, B. Giardine, C. Riemer et al., “Improvements in the HbVar database of human hemoglobin variants and thalassemia mutations for populations and sequence variation studies,” Nucleic Acids Research, vol. 32, pp. D537–D41, 2004.
[3] A. Papachatzopoulou, A. Kourakli, E. F. Stavrou et al., “Region-specific genetic heterogeneity of HBB mutation distribution in South-Western Greece,” Hemoglobin, vol. 34, no. 4, pp. 333–342, 2010.
[4] G. P. Patrinos, S. Van Baal, M. B. Petersen, and M. N. Papadakis, “Hellenic national mutation database: a prototype database for mutations leading to inherited disorders in the hellenic population,” Human Mutation, vol. 25, no. 4, pp. 327–333, 2005.
[5] B. Modell, M. Khan, and M. Darlison, “Survival in β-thalassaemia major in the UK: data from the UK thalassemia register,” The Lancet, vol. 355, no. 9220, pp. 2051–2052, 2000.
[6] C. Borgna-Pignatti, S. Rugolo, P. De Stefano et al., “Survival and complications in patients with thalassemia major treated
with transfusion and deferoxamine," *Haematologica*, vol. 89, no. 10, pp. 1187–1193, 2004.

[7] R. Monastero, G. Monastero, C. Ciaccio, A. Padovani, and R. Camarda, "Cognitive deficits in beta-thalassemia major," *Acta Neuroligica Scandinavica*, vol. 102, no. 3, pp. 162–168, 2000.

[8] M. Economou, D. I. Zafeiriou, E. Kontopoulos et al., "Neurophysiologic and intellectual evaluation of beta-thalassemia patients," *Brain and Development*, vol. 28, no. 1, pp. 14–18, 2006.

[9] D. I. Zafeiriou, M. Economou, and M. Athanasiou-Metaxa, "Neurological complications in beta-thalassemia," *Brain and Development*, vol. 28, no. 8, pp. 477–481, 2006.

[10] J. E. Ware, M. Kosinski, and S. D. Keller, *SF-36 Physical and Mental Health Summary Scales: A User’s Manual*, The Health Institute, Boston, Mass, USA, 1994.

[11] B. S. Wallston and K. A. Wallston, "Health locus of control," in *Research With the Locus of Control Construct*, H. Lefcourt, Ed., vol. 1, Academic Press, New York, NY, USA, 1981.

[12] K. M. Musallam, B. Khoury, R. Abi-Habib et al., "Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights," *European Journal of Haematology*, vol. 87, no. 1, pp. 73–79, 2011.

[13] C. Politis, A. Di Palma, M. Fisfis et al., "Social integration of the older thalassaemic patient," *Archives of Disease in Childhood*, vol. 65, no. 9, pp. 984–986, 1990.

[14] R. Origa, P. Bina, A. Agus et al., "Combined therapy with deferasiprone and desferrioxamine in thalassemia major," *Haematologica*, vol. 90, no. 10, pp. 1309–1314, 2005.

[15] R. A. Risdon, M. Barry, and D. M. Flynn, "Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassaemia," *Journal of Pathology*, vol. 116, no. 2, pp. 83–95, 1975.

[16] G. Jean, S. Terzoli, and R. Mauri, "Cirrhosis associated with multiple transfusions in thalassaemia," *Archives of Disease in Childhood*, vol. 59, no. 1, pp. 67–70, 1984.

[17] A. Pathare, A. Taher, and S. Daar, "Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major," *Annals of Hematology*, vol. 89, no. 4, pp. 405–409, 2010.

[18] A. Pepe, A. Meloni, M. Capra et al., "Deferasirox, deferasiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging," *Haematologica*, vol. 96, no. 1, pp. 41–47, 2011.

[19] M. D. Cappellini, M. Bejaoui, L. Agaoglu et al., "Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia," *Clinical Therapeutics*, vol. 29, no. 5, pp. 909–917, 2007.

[20] A. Taher, A. Al Jefri, M. S. Elalfy et al., "Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-thalassemia: results from the ESCALATOR trial," *Acta Haematologica*, vol. 123, no. 4, pp. 220–225, 2010.

[21] L. Abetz, J. F. Baladi, P. Jones, and D. Rofail, "The impact of iron overload and its treatment on quality of life: results from a literature review," *Health and Quality of Life Outcomes*, vol. 4, p. 73, 2006.

[22] Z. Pakbaz, M. Treadwell, R. Yamashita et al., "Quality of life in patients with thalassemia intermedia compared to thalassemia major," *Annals of the New York Academy of Sciences*, vol. 1054, pp. 457–461, 2005.